Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir retreatment in genotype 3 hepatitis C with cirrhosis after pegylated interferon/ribavirin failure
2013-003729-27Phase 4Completed
- Sponsor
- Queen Mary University of London
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telaprevir in hepatitis C virus infection, sponsored by Queen Mary University of London. Primary endpoint: Sustained virological response. Started Oct 2013; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2013-003729-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003729-27.